Business Wire

NY-MSCI

9.9.2019 14:02:19 CEST | Business Wire | Press release

Share
MSCI Appoints Salli Schwartz Head of Investor Relations and Treasurer

MSCI Inc. (NYSE: MSCI), a leading provider of critical decision support tools and services for the global investment community, announced today that Salli Schwartz has been appointed Head of Investor Relations and Treasurer, effective September 16, 2019.

“We are thrilled that Salli is joining MSCI. Her 20 years in financial services, particularly in establishing and executing capital strategy, developing robust investor communication programs and managing relationships with shareholders, ratings agencies and sell side analysts, will ensure that we continue to maximize shareholder value,” said Linda S. Huber, Chief Financial Officer of MSCI.

“MSCI is continuing to evolve and grow rapidly, and I am excited to work with Linda and the Executive Committee to enhance its capital management strategy and to tell the company’s story to the investor community,” said Ms. Schwartz.

Ms. Schwartz previously served as the Global Head of Strategic Capital Management and Treasurer of Moody’s Corporation. She formed Moody’s Strategic Capital Management Group by combining the Investor Relations and Treasury teams, comprised of 20 global professionals. She also held other key senior positions during her 12-year tenure at Moody’s Corporation, including Global Head of Investor Relations and Communications as well as various Corporate Development roles. Ms. Schwartz began her career in Legg Mason’s investment banking group and was part of the financial management rotational program at Citigroup.

Ms. Schwartz holds an M.B.A. from the Johnson Graduate School of Management at Cornell University and a B.A. in History and Sociology of Science from the University of Pennsylvania.

About MSCI Inc.

MSCI is a leading provider of critical decision support tools and services for the global investment community. With over 45 years of expertise in research, data and technology, we power better investment decisions by enabling clients to understand and analyze key drivers of risk and return and confidently build more effective portfolios. We create industry-leading research-enhanced solutions that clients use to gain insight into and improve transparency across the investment process. To learn more, please visit www.msci.com . MSCI#IR

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to future events or to future financial performance and involve known and unknown risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these statements. In some cases, you can identify forward-looking statements by the use of words such as “may,” “could,” “expect,” “intend,” “plan,” “seek,” “anticipate,” “believe,” “estimate,” “predict,” “potential” or “continue,” or the negative of these terms or other comparable terminology. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond MSCI’s control and that could materially affect actual results, levels of activity, performance or achievements.

Other factors that could materially affect actual results, levels of activity, performance or achievements can be found in MSCI’s Annual Report on Form 10-K for the fiscal year ended December 31, 2018 filed with the Securities and Exchange Commission (“SEC”) on February 22, 2019 and in quarterly reports on Form 10-Q and current reports on Form 8-K filed or furnished with the SEC. If any of these risks or uncertainties materialize, or if MSCI’s underlying assumptions prove to be incorrect, actual results may vary significantly from what MSCI projected. Any forward-looking statement in this press release reflects MSCI’s current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to MSCI’s operations, results of operations, growth strategy and liquidity. MSCI assumes no obligation to publicly update or revise these forward-looking statements for any reason, whether as a result of new information, future events, or otherwise, except as required by law.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SCP Standard Capital Partners AG: Fabian Becker Appointed Chairman of the Management Board and CEO9.7.2026 14:51:00 CEST | Press release

The Supervisory Board of SCP Standard Capital Partners AG (WKN: A12UPJ | ISIN: DE000A12UPJ7 | XETRA ticker: CAP) resolved today to appoint Mr. Fabian Becker as Chairman of the Management Board and Chief Executive Officer (CEO), effective as of 9 July 2026. Ms. Stephanie Schettler-Köhler will remain a member of the Management Board and will assume the role of Chief Operating Officer (COO). View source version on businesswire.com: https://www.businesswire.com/news/home/20260709982268/en/

Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis9.7.2026 14:45:00 CEST | Press release

Teva secures exclusive global rights to commercialize Polpharma Biologics’ biosimilar candidate to Ocrevus® (ocrelizumab), including both intravenous and subcutaneous formulations.Agreement advances Teva’s Pivot to Growth strategy by expanding its biosimilars pipeline through strategic collaborations.Agreement reflects both companies’ commitment to broadening access to biologic medicines. Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE: and TASE: TEVA) and Polpharma Biologics International AG today announced a global licensing agreement granting Teva exclusive rights to commercialize both formulations of Polpharma Biologics’ proposed biosimilar to Ocrevus®1 (ocrelizumab), upon regulatory approval. This strategic agreement is expected to combine Polpharma Biologics’ proven biosimilar development expertise with Teva’s commercial footprint and capabilities. This press release features multimedia. View the full release here: https://www.bus

Elliptic Announces Circle’s Participation in Agentic Design Partner Program9.7.2026 14:15:00 CEST | Press release

Following investment from Circle Ventures, the corporate venture arm of Circle Elliptic, the global leader in digital asset intelligence, today announced that an affiliate of Circle Internet Group, Inc. (‘Circle’) (NYSE:CRCL) has joined its Agentic Design Partner Program, bringing together infrastructure providers, compliance teams, and technology leaders to help shape compliance solutions for autonomous, AI-driven financial activity. This momentum follows an investment from Circle Ventures, the corporate venture arm of Circle, and builds on a longstanding collaboration between the companies. Circle has been an Elliptic customer for multiple years and has expanded its use of Elliptic’s compliance capabilities across a range of digital asset initiatives. As stablecoins, tokenized assets, and AI-powered applications become increasingly integrated into financial services, new compliance challenges are emerging. Elliptic’s agentic compliance layer addresses these challenges by combining un

Russell Investments Announces New Long-Term Owners9.7.2026 14:00:00 CEST | Press release

An investor consortium led by B Capital and including CalPERS will provide long-term capital to expandRussell Investments’ client capabilities and accelerate innovation Russell Investments, the global investment solutions provider, today announced that an investor consortium (the “Investor Consortium”) led by B Capital, a global multi-stage investment firm, and including California Public Employees' Retirement System ("CalPERS"), has agreed to acquire the firm from TA Associates (“TA”) and Reverence Capital Partners (“RCP”). The transaction comes as Russell Investments marks over $416 billion in global assets under management (AUM) and has experienced more than 15% organic growth over the past two years. Russell Investments has been a trusted, independent partner to its clients for over 90 years. Its open-architecture model delivers portfolio solutions that source from the full landscape of the asset management industry across public and private markets. With a shared vision for the co

Esri and Global Partners Release HydroSHEDS v2 for the Americas9.7.2026 14:00:00 CEST | Press release

Next-Generation Hydrographic Framework Delivers Unprecedented Detail for Watershed and River Network Analysis Esri and its global partners have released HydroSHEDS v2, providing high-resolution hydrographic data for North, Central, and South America. Developed with World Wildlife Fund in the US, McGill University and Confluvio Consulting in Canada, and the German Aerospace Center (DLR), the initiative reflects global collaboration in hydrologic science and geospatial technology. HydroSHEDS v2 leverages TanDEM-X elevation data and Arc Hydro workflows to deliver more accurate drainage networks, watershed boundaries, and hydrologic connectivity. The datasets support applications such as flood risk assessments, climate resilience studies, systematic conservation planning, water resource management, and environmental decision-making. HydroSHEDS v2 datasets are available through ArcGIS Living Atlas, with additional global releases planned as part of a phased rollout. Esri has made HydroSHEDS

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye